Delivery systems for selective androgen receptor modulators

The oral drug delivery system for SARM compounds with multiple compartments addresses the need for delayed release, enhancing therapeutic efficacy and compatibility with other medications by controlling the timing and location of absorption.

WO2026241607A1PCT designated stage Publication Date: 2026-11-19VERU INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028314
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-08-11
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

There is a need for reliable and patient-friendly delivery systems for the delayed release of selective androgen receptor modulator (SARM) compounds to provide consistent and effective treatments for various medical conditions, including muscle wasting and breast cancer.

Method used

An oral drug delivery system with multiple compartments for SARM compounds, including a first immediate release compartment in the stomach, a protective base compartment in the intestine, and a second delayed release compartment, allowing a defined time interval between releases in the gastrointestinal tract.

Benefits of technology

The system provides a dual release of SARM compounds with controlled timing, reducing adverse effects and optimizing absorption for improved therapeutic efficacy and compatibility with other medications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028314_19112026_PF_FP_ABST
    Figure US2026028314_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to drug delivery systems for oral administration of selective androgen receptor modulator (SARM) compounds disclosed herein. The drug delivery systems allow a modified release of the SARM compounds through two or more phases in the gastrointestinal tract. The drug delivery systems employ multiple three-dimensionally printed compartments.
Need to check novelty before this filing date? Find Prior Art

Description

P-657030-PCDELIVERY SYSTEMS FOR SELECTIVE ANDROGEN RECEPTOR MODULATORSCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority of US provisional application Nos.63 / 805,870 filed on May 14, 2025 and 63 / 861,886 filed on August 11, 2025 hereby incorporated by reference.FIELD OF THE INVENTION

[0002] The present invention relates to drug delivery systems for oral administration of selective androgen receptor modulator (SARM) compounds disclosed herein. The drug delivery systems allow a modified release of the SARM compounds through two or more phases in the gastrointestinal tract. The drug delivery systems employ multiple three-dimensionally printed compartments.BACKGROUND OF THE INVENTION

[0003] Selective androgen receptor modulator (SARM) compounds disclosed herein have shown tissue-selective, dose-dependent increases in lean body mass, fat mass reduction, and improvement in insulin resistance. SARM treatment in elderly men and postmenopausal women with and without active muscle wasting consistently results in reduction in fat mass and significant increases in lean body mass with improvements in muscle strength and physical function.

[0004] The SARM compounds including Formula IX exert beneficial effects on body composition in patients taking incretin (receptor) agonist or antagonist containing drugs including GLP-1 or GIP receptor agonists or antagonists or other classes of weight loss drugs.

[0005] These SARM compounds are also found useful for treatment of breast cancer, e.g., metastatic breast cancer, refractory breast cancer, AR-positive breast cancer, ER-positive, HER2-positive, triple negative breast cancer, advanced breast cancer, and breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropinreleasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI)(letrozole, anastrozole,P-657030-PCexemestane), fulvestrant, cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Vorzenio), trilaciclib, lerociclib), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3 -kinase 5 subunit alpha (PI3Ka)), mTOR inhibitor (everolimus), poly ADP ribose polymerase (PARP) inhibitor (olaparib (Lynparza) or talazoparib (Talzenna)), human epidermal growth factor receptor 2 (HER2) kinase inhibitor (lapatinib, neratinib (Nerlynx), dacomitinib (Vizimpro), or tucatinib (Tukysa)), HER2 antibody (trastuzumab (Herceptin), pertuzumab (Peijeta), margetuximab-cmkb (Margenza)), HER2 antibody drug conjugate (HERZ ADC) (am-trastuzumabderuxtecan-nxki (Enhertu), ado-trastuzumab emtansine (Kadcyla), or pertuzumab / trastuzumab / hyaluronidase-zzxf (Phesgo)), atezolizumab (Tecentriq) (PD-L1 blocking antibody), pembrolizumab (Keytruda) (PD-L1 blocking antibody), sacituzumab govitecan (Trodelvy) (antibody drug conjugate for TNBC), and / or bevacizumab (Avastin) treatments.

[0006] Currently there exists a need for reliable and patient-friendly delivery systems for the delayed release of SARM compounds that can provide consistent and effective treatments for various medical conditions.SUMMARY OF THE INVENTION

[0007] In one aspect, the present invention provides an oral drug delivery system for a modified release administration of a selective androgen receptor modulator (SARM) compound of Formula I to a subject, wherein the system comprises multiple distinct compartments comprising:(i) Compartment 1: a first immediate release SARM-containing compartment that is soluble in the fluids of the stomach;(ii) Compartment 2: a base compartment without SARM that is contiguous with Compartment 1 and is insoluble in the stomach but soluble in the intestine; and(iii) Compartment 3: a second (delayed) release SARM-containing compartment that (the inner core or central core) is completely enclosed by Compartment 2 such that its contents are protected until Compartment 2 dissolves in the intestine and causes the delayed release of Compartment 3 in the intestine;wherein said drug delivery system provides a dual release of said SARM compound in vivoP-657030-PCcharacterized by a defined time interval between a first immediate release of the SARM compound in stomach and a second release of the SARM compound in the intestine;wherein said SARM compound is represented by a structure of Formula I:whereinX is a bond, O, CH2, NH, S, Se, PR, NO, or NR;G is O or S;T is OH, OR, -NHCOCH3, or NHCOR;R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF, aryl, phenyl, halogen, alkenyl, or OH;Ri is CH3, CH2F, CHF2, CF3, CH2CH3, or CF2CF3;R2is H, F, Cl, Br, I, CH3, CF3, OH, CN, NO2, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, N(R)2, or SR;R3 is H, F, Cl, Br, I, CN, NO2, COR, COOH, CONHR, CF3, or Sn(R)3, or R3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:Z is NO2, CN, COR, COOH, or CONHR;Y is CF3, F, Br, Cl, I, CN, or Sn(R)3;Q is CN, alkyl, halogen, N(R)2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R, or SR;P-657030-PCor Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B, or C:n is an integer of 1-4; andm is an integer of 1-3, oran optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an N-oxide, or a crystal thereof.

[0008] In some embodiments, said SARM compound is represented by a structure of Formula II:whereinX is a bond, O, CH2, NH, Se, PR, or NR;G is O or S;T is OH, OR, -NHCOCH3, or NHCOR;Z is NO2, CN, COR, COOH, or CONHR;Y is I, CF3, Br, Cl, or Sn(R)3;Q is CN, alkyl, halogen, N(R)2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R, or SR;or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B, or C:P-657030-PCR is a C1-C4 alkyl, aryl, phenyl, alkenyl, hydroxyl, a C1-C4 haloalkyl, halogen, or haloalkenyl; andRi is CH3, CF3, CH2CH3, or CF2CF3; oran optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an A'-oxide, or a crystal thereof.

[0009] In some embodiments, the time interval between the first immediate release period and the second (delayed) release phase is from 1 hour to 12 hours.

[0010] In another aspect, the present invention provides a method (i) for preventing, reducing, or treating adverse effects caused by a weight loss drug or (ii) for maintenance or improvement of body composition in a subject who is in need of treatment with the weight loss drug, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, wherein the SARM is formulated by the drug delivery system of the invention as described herein.

[0011] These and other aspects of the invention will be appreciated from the ensuing descriptions of the figures and detailed description of the invention.BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.

[0013] Figure 1 depicts a geometry overview of 3-compartment tablets on the invention: Tab 358, Tab 359, Tab 360, Tab 365, and Tab 366. These tablets are comprised of three separate compartments: 1) P242 is an immediate release (IR) paste that comprises Compartment 1 of the invention depicted at the top of the tablets, 2) P276 is the paste that forms the Buffer Shell depicted below the P242-containing Compartment 1 and comprises Compartment 2, and 3) P287 is the paste that forms the Inner Core (depicted as enclosed by P276- containing Compartment 2) andP-657030-PCcomprises Compartment 3. The composition of P276, P242, and P287 are defined elsewhere herein. Tablets 358-360 contained 1 mg of Formula IX in Compartment 1 and 2 mg of Formula IX in Compartment 3, whereas Tablets 365 and 366 contained 2 mg of Formula IX in Compartment 1 and 1 mg of Formula IX in Compartment 3.

[0014] Figure 2 depicts in vitro dissolution of Tab 360 (three experiments). Tab 360 as described above and herein throughout was dissolved in vitro and release of Formula IX (labeled as Enobosarm) was monitored over time.

[0015] Figure 3 depicts in vitro dissolution data of Tab 358 (three experiments). Tab 358 as described above and herein throughout was dissolved in vitro and release of Formula IX (labeled as Enobosarm) was monitored over time.

[0016] Figure 4 depicts in vitro dissolution profiles of 3 mg Capsules (immediate release (IR); left-most curve), Tab 358 (modified release; middle curve), and Tab 360 (modified release; rightmost curve). The immediate release capsule releases all of the API (3 mg of Formula IX) in a single release phase, whereas the modified release Tab 358 has an initial 1 mg release and a subsequent 2 mg delayed release of API (Formula IX). Tab 360 was similar to Tab 358 with regard to the timing of the initial 1 mg release, but the subsequent 2 mg delayed release of API (Formula IX) occurred later for Tab 360 than Tab 358. Accordingly, Tab 358 and Tab 360 can be expected to have distinct pharmacokinetic (PK) profiles in vivo when compared to the immediate release 3 mg Capsule. Further, Tab 358 and Tab 360 can also be expected to produce distinct PK profiles from each other such as a lower Cmax and higher tmax in vivo for Tab 360 than Tab 358.

[0017] Figure 5 depicts plasma levels of Formula IX after oral administration to pigs of the immediate release 3 mg Capsule (AUC 3540 ± 786 hr*ng / mL; left-most curve) vs. modified release tablets labeled Tab 358 (AUC 3460 ± 510 hr*ng / mL; middle curve) and Tab 360 (AUC 2920 ± 551 hr*ng / mL; right-most curve). As expected from Figure 4, the delayed release tablets of the invention produced PK profiles that are distinct from the immediate release Capsule without increasing AUC.

[0018] Figure 6 depicts a comparison of the plasma concentration -time curve between two novel formulations in humans. Form 1 is the same as Tab 358 in Examples 1-3 and Form 2 is the same as Tab 360 in Examples 1-3, as described in more detail in Example 5.P-657030-PC

[0019] It will be appreciated that for simplicity and clarity of illustration, elements shown in the figures have not necessarily been drawn to scale. For example, the dimensions of some of the elements may be exaggerated relative to other elements for clarity. Further, where considered appropriate, reference numerals may be repeated among the figures to indicate corresponding or analogous elements.DETAILED DESCRIPTION OF THE INVENTION

[0020] The present invention relates to an oral drug delivery system for a modified release administration of drugs. The drug delivery system of the present invention contains multiple distinct, specific “compartments” which allow a modified release of the drugs at two or more specific locations in the gastrointestinal tract, for example, one in the stomach and one in the intestine. Such a drug delivery system can be characterized by an adjustable but defined time interval between two distinct releases of the drug at two distinct locations in the GI. That is to say, the time interval between the start of a first release of the drug and the start of a second (delayed) release of the drugs is consistent and can be increased or decreased as desired. The system can also control the total release time and duration for the drug’s release. The delivery system of the invention allows fast therapeutic action after a first release and further retains blood drug concentration for long periods after a second (delayed) release.

[0021] In one aspect, the present invention provides a drug delivery system for oral administration of a selective androgen receptor modulator (SARM) compound of Formula I described herein. The drug delivery system of the present invention contains multiple distinct compartments which provide two or more phases in the release of the SARM compound in vivo. In some embodiments, a time interval can be adjusted, defined, or modified between a first release of the SARM compound in stomach and a second release of the SARM compound in the intestine

[0022] In one aspect, the present invention provides an oral drug delivery system for a modified release administration of a selective androgen receptor modulator (SARM) compound of Formula I to a subject, wherein the system comprises multiple distinct compartments comprising:(i) Compartment 1: a first immediate release SARM-containing compartment that is soluble in the fluids of the stomach, frequently referred to as the immediate release or firstP-657030-PCcompartment;(ii) Compartment 2: a base compartment without SARM that is contiguous with Compartment 1 and is insoluble in the stomach but soluble in the intestine providing protection against dissolution in the stomach while maintaining the structure of the central core; frequently referred to as the coating, buffer shell, central shell, or second compartment; and(iii) Compartment 3: a second (delayed) release SARM-containing compartment (the inner core or central core) that is completely enclosed by Compartment 2 such that its contents are protected until Compartment 2 dissolves in the intestine and causes the delayed release of Compartment 3 in the intestine; wherein Compartment 3 may also have modifiers within the compartment and may further delay the full release and change the profile of the released drug product;wherein said drug delivery system provides a dual release of said SARM compound in vivo characterized by a defined time interval between a first immediate release of the SARM compound in stomach and a second (delayed) release of the SARM compound in the intestine; and wherein said SARM compound is represented by a structure of Formula I, II, VIII, IX, X, XI, XII, XIII, or XIV as described herein.

[0023] In one aspect, the present invention provides an oral drug delivery system for a modified release administration of a selective androgen receptor modulator (SARM) compound of Formula I to a subject, wherein the system comprises multiple distinct compartments comprising:(i) Compartment 1: a first immediate release SARM-containing compartment that is soluble in the fluids of the stomach;(ii) Compartment 2: a base compartment without SARM that is contiguous with Compartment 1 and is insoluble in the stomach but soluble in the intestine,(iii) Compartment 3: a second (delayed) release SARM-containing compartment (the inner core or central core) that is completely enclosed by Compartment 2 such that its contents are protected until Compartment 2 dissolves in the intestine and causes the delayed release of Compartment 3 in the intestine.wherein said drug delivery system provides a dual release of said SARM compound in vivo characterized by a defined time interval between a first release of the SARM compound in stomach and a second release of the SARM compound in the intestine;P-657030-PCwherein said SARM compound is represented by a structure of Formula I:whereinX is a bond, O, CH2, NH, S, Se, PR, NO, or NR;G is O or S;T is OH, OR, -NHCOCH3, or NHCOR;R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or OH;Ri is CH3, CH2F, CHF2, CF3, CH2CH3, or CF2CF3;R2is H, F, Cl, Br, I, CH3, CF3, OH, CN, NO2, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, N(R)2, or SR;R3is H, F, Cl, Br, I, CN, NO2, COR, COOH, CONHR, CF3, or Sn(R)3, or R3together with the benzene ring to which it is attached forms a fused ring system represented by the structure:Z is NO2, CN, COR, COOH, or CONHR;Y is CF3, F, Br, Cl, I, CN, or Sn(R)3;Q is CN, alkyl, halogen, N(R)2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R, or SR;or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B, or C:P-657030-PCA B C;n is an integer of 1-4; andm is an integer of 1-3, oran optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an A -oxi de, or a crystal thereof.

[0024] In one aspect, the present invention provides an oral drug delivery system for a modified release administration of a selective androgen receptor modulator (SARM) compound of Formula II:whereinX is a bond, O, CH2, NH, Se, PR, or NR;G is O or S;T is OH, OR, -NHCOCH3, or NHCOR;Z is NO2, CN, COR, COOH, or CONHR;Y is I, CF3, Br, Cl, or Sn(R)3;Q is CN, alkyl, halogen, N(R)2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R, or SR;or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B, or C:P-657030-PCA B C;R is a C1-C4 alkyl, aryl, phenyl, alkenyl, hydroxyl, a C1-C4 haloalkyl, halogen, or haloalkenyl; andRi is CH3, CF3, CH2CH3, or CF2CF3; oran optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an N-oxide, or a crystal thereof.

[0025] In one embodiment, the SARM compound is represented by a structure of Formulas VIII, IX, X, XI, XII, XIII, and XIV:P-657030-PCXIV, oran optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an / V-oxide, or a crystal thereof.

[0026] In one embodiment, the SARM compound is represented by a structure of Formula IX,P-657030-PCIX, oran optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an A'-oxide, or a crystal thereof.

[0027] In some embodiments of the method of the invention, the relative compartment dimensions are adjustable to allow modification of the time interval between the first immediate release period and the second (delayed) release phase.

[0028] In some embodiments, as used herein, the “modification of the time interval” refers to the ability to change or adjust compartment dimensions to obtain a desired time interval for delivery of SARM compounds between the first immediate release period and the time of a second (delayed) release phase.

[0029] In some embodiments of the invention, the drug delivery system is a 3-dimensional solid formulation (e.g., a solid oral dosage form) comprising multiple compartments. These compartments may have various shapes or sizes and can comprise any drug compositions (e.g., SARM compounds of the invention) or a formulation thereof (e.g., an immediate release formulation).

[0030] In some embodiments, the height or width of each compartment is varied in order to modify the timing of the second (delayed) release phase.

[0031] In some embodiments, the oral drug delivery system of the invention has a shape as depicted in Scheme 1, wherein the dimensions of heights A, B, C, D, and D' and widths E, E', and F of the system are illustrated as below:P-657030-PCScheme 1

[0032] In some embodiments, (a) the first immediate release compartment (a top compartment 1) has a height of from 0.1 mm to 5 mm (Height A). In other embodiments, Height A is from about 0.1 mm to about 5 mm. In some embodiments, Height A is from about 0.3 mm to about 5 mm, or from 0.3 mm to about 4.5 mm. In some embodiments, Height A is about 0.1 mm, 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, or 1.0 mm. In other embodiments, Height A is from about 0.5 mm to about 4.0 mm, or from 1.0 mm to about 3.5 mm, or from 1.0 mm to about 3.0 mm.

[0033] In some embodiments, (b) the base compartment (in light shading) has a height of from 0.1 mm to 15 mm (Height B). In other embodiments, Height B is from about 0.1 mm to about 12 mm. In some embodiments, Height B is from about 0.1 mm to about 10 mm, or from 0.1 mm to about 7.5 mm. In some embodiments, Height B is about 0.1 mm, 0.2 mm, 0.5 mm, 0.7 mm, 1.0 mm, 1.5 mm, 2.0 mm, 2.5 mm, 3.0 mm, or 4.0 mm. In other embodiments, Height B is from about 1.0 mm to about 15.0 mm, or from 1.0 mm to about 12.0 mm, or from 1.0 mm to about 10.0 mm, or from 1.0 mm to about 7.0 mm. or from 1.0 mm to about 5.0 mm.

[0034] In some embodiments, (c) the second (immediate or delayed) release compartment (lower dark compartment or Compartment 3) has a height of from 0.01 mm to 8 mm (Height C). In other embodiments, Height C is from about 0.01 mm to about 7 mm. In some embodiments, Height C is from about 0.01 mm to about 6 mm, or from 0.01 mm to about 5 mm. In some embodiments, Height C is about 0.01 mm, 0.02 mm, 0.05 mm, 0.07 mm, 0.1 mm, 0.2 mm, 0.3 mm, 0.5 mm, 1,0 mm, 1.5 mm, 2.0 mm. In other embodiments, Height C is from about 1.0 mm to about 8.0 mm, or from 1.0 mm to about 6.0 mm, or from 1.0 mm to about 4.0 mm, or from 1.0 mm to about 3.0 mm, or from 1.0 mm to about 2.0 mm.

[0035] In some embodiments, the height of the base compartment above the second (delayed) release compartment is from 0.01 mm to 3.5 mm (Height D). In other embodiments, Height D is from about 0.02 mm to about 3.5 mm. In some embodiments, Height D is from about 0.03 mm to about 3.5 mm, or from 0.04 mm to about 3.5 mm. In some embodiments, Height D is about 0.01 mm, 0.02 mm, 0.03 mm, 0.04 mm, 0.05 mm, 0.06 mm, 0.07 mm, 0.08 mm, 0.09 mm, 0.1 mm, 0.2P-657030-PCmm, or 0.3 mm. In other embodiments, Height D is from about 0.1 mm to about 3.5 mm, or from 0.1 mm to about 3.0 mm, or from 0.1 mm to about 2.5 mm, or from 0.1 mm to about 2.0 mm.

[0036] In some embodiments, the height of the base compartment below the second (delayed) release compartment is from 0.01 mm to 3.5 mm (Height D'). In other embodiments, Height D' is from about 0.02 mm to about 3.5 mm. In some embodiments, Height D’ is from about 0.03 mm to about 3.5 mm, or from 0.04 mm to about 3.5 mm. In some embodiments, Height D’ is about 0.01 mm, 0.02 mm, 0.03 mm, 0.04 mm, 0.05 mm, 0.06 mm, 0.07 mm, 0.08 mm, 0.09 mm, 0.1 mm, 0.2 mm, or 0.3 mm. In other embodiments, Height D’ is from about 0.1 mm to about 3.5 mm, or from 0.1 mm to about 3.0 mm, or from 0.1 mm to about 2.5 mm, or from 0.1 mm to about 2.0 mm.

[0037] In some embodiments, Height D and Height D' are the same height. In other embodiments, Height D and Height D' have a different height from each other.

[0038] In some embodiments, the width of the base compartment on either side of the second (delayed) release compartment is from 0.01 mm to 10 mm (Widths E and E’). In other embodiments, Widths E and E' are each from about 0.01 mm to about 8 mm. In some embodiments, Widths E and E' are each from about 0.01 mm to about 6 mm, or from 0.01 mm to about 5 mm. In some embodiments, Widths E and E' are each about 0.01 mm, 0.02 mm, 0.05 mm, 0.07 mm, 0.1 mm, 0.2 mm, 0.5 mm, 1,0 mm, 1.5 mm, or 2.0 mm. In other embodiments, Widths E and E' are each from about 1.0 mm to about 10.0 mm, or from 1.0 mm to about 8.0 mm, or from 1.0 mm to about 6.0 mm, or from 1.0 mm to about 5.0 mm, or from 1.0 mm to about 3.0 mm. In some embodiments, Width E and Width E' are the same width. In other embodiments, Width E and Width E' have a different width from each other.

[0039] In some embodiments, the width of the second (delayed) release compartment is from 0.01 mm to 20 mm (Width F). In other embodiments, Width F is from about 0.01 mm to about 15 mm. In some embodiments, Width F is from about 0.01 mm to about 10 mm, or from 0.01 mm to about 5 mm. In some embodiments, Width F is about 0.01 mm, 0.02 mm, 0.05 mm, 0.07 mm, 0.1 mm,P-657030-PC0.2 mm, 0.5 mm, 1.0 mm, 1.5 mm, 2.0 mm, 3 mm, 4 mm, 5 mm, 6 mm, 8mm, or 10 mm. In other embodiments, Width F is from about 1.0 mm to about 15 mm, or from 1.0 mm to about 12 mm, or from 1.0 mm to about 10 mm, or from 1.0 mm to about 8.0 mm, or from 1.0 mm to about 5.0 mm.

[0040] In some embodiments of the drug delivery system of the invention, Heights A, B, C, D, and D' and Widths E, E', and F are as depicted below (Scheme 1):Scheme 1wherein(a) Compartment 1: a first immediate release compartment (a top compartment) has a height of from 0.1 mm to 5 mm (Height A),(b) Compartment 2: a base compartment (in light shading) has a height of from 0.1 mm to 15 mm (Height B),(c) Compartment 3: a second (delayed) release compartment (lower dark compartment) has a height of from 0.01 mm to 8 mm (Height C),wherein the height of the base compartment above the second (delayed) release compartment is from 0.01 mm to 3.5 mm (Height D),wherein the height of the base compartment below the second (delayed) release compartment is from 0.01 mm to 3.5 mm (Height D'),wherein the widths of the base compartment on either side of the second (delayed) release compartment is independently from 0.01 mm to 10 mm (Widths E and E’), andwherein the width of the second (delayed) release compartment is from 0.01 mm to 20 mm (Width F).

[0041] In some embodiments, the size of the tablets are proportionally modified (either increasedP-657030-PCor decreased) to improve the handleability and ability of some patients to swallow the tablets in the range of 2 to 10 mm diameter and 2 to 10 mm height. In some embodiments, tablets with a width of <10 mm and a heighth of <10 mm can be difficult to handle (poor handleability) and / or difficult to swallow. The invention includes drug delivery systems wherein the dimensions and concentrations are increased to address this issue. In some embodiments, the specific compartment dimensions and concentrations used in the drug delivery system of the invention are decreased or increased to improve handleability and swallowability. In some embodiments, the in vitro release characteristics are not altered by the decreased or increased compartment dimensions and concentrations. In some embodiments, the time interval between in vitro release phases is not altered by the decreased or increased compartment dimensions and concentrations. In some embodiments, the in vivo pharmacokinetic characteristics are not altered by the decreased or increased compartment dimensions and concentrations. In some embodiments, the compartment dimensions and concentrations can be increased or decreased in parallel to achieve the same improvements of the invention relative to 1R formulations. In some embodiments, some compartment dimensions are increased or decreased while others are not altered. In some embodiments, some compartment API conentrations are increased or decreased to compensate for the changes in compartment dimensions. In some embodiments, time interval between immediate and delayed SARM release phases is not substantially altered by changes in compartment dimensions and concentrations for different drug delivery systems of the invention. In some embodiments, Cmax values are not substantially altered by changes in compartment dimensions and concentrations for different drug delivery systems of the invention. In some embodiments, the tmax values are not substantially altered by changes in compartment dimensions and concentrations for different drug delivery systems of the invention. In some embodiments, the AUC values are not substantially altered by changes in compartment dimensions and concentrations for different drug delivery systems of the invention. In some embodiments, such adjustments to compartment dimensions and concentrations can be made proportionally such that in vitro release and in vivo pharmacokinetic profiles are substantially unaltered. In some cases, tablets with width of <10 mm and heighth of <10 mm can be difficult to handle (poor handleability) and / or difficult to swallow. The invention includes drug delivery systems wherein the dimensions and concentrations are increased to address this issue.P-657030-PCIn some embodiments, the time interval between the first immediate release period and the second (delayed) release phase is from 0.5 hour to 12 hours. In some embodiments, the time interval between the first immediate release period and the second (delayed) release phase is from 0.5 hour to 4 hours. In some embodiments, the time interval between the first immediate release period and the second (delayed) release phase is from 0.5 hour to 2 hours. In some embodiments, the time interval between the first immediate release period and the second (delayed) release phase is from 1 hour to 12 hours. In some embodiments, the time interval between the first immediate release period and the second (immediate or delayed) release phase is from 1 hour to 10 hours. In other embodiments, the time interval between the first immediate release period and the second (immediate or delayed) release phase is from 2 hours to 8 hours. In some embodiments, the time interval between the first immediate release period and the second (immediate or delayed) release phase is from 2 hours to 6 hours. In some embodiments, the time interval between the first immediate release period and the second (immediate or delayed) release phase is from 4 hours to 12 hours. In some embodiments, the time interval between the first immediate release period and the second (immediate or delayed) release phase is from 4 hours to 10 hours. In other embodiments, the time interval between the first immediate release period and the second (immediate or delayed) release phase is from 4 hours to 8 hours. In some embodiments, the time interval between the first immediate release period and the second (immediate or delayed) release phase is from 4 hours to 6 hours.

[0042] In some embodiments, the first immediate release compartment (stomach-soluble) comprises 0.1 mg to 20 mg of the SARM compound of Formula I. In some embodiments, the first immediate release compartment comprises 0.5 mg to 10 mg of the SARM compound of Formula I. In other embodiments, the first immediate release compartment comprises 0.1 mg, 0.3 mg, 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 9 mg, 10 mg, 12 mg, 18 mg, or 20 mg of the SARM compound of Formula I disclosed herein. In certain embodiments, the SARM compound is the compound of Formula IX.

[0043] In some embodiments, the second (immediate or delayed) release compartment (intestine soluble) comprises 0.1 mg to 20 mg of the SARM compound of Formula I. In some embodiments,P-657030-PCthe second (immediate or delayed) release compartment comprises 0.5 mg to 10 mg of the SARM compound of Formula I. In other embodiments, the second (immediate or delayed) release compartment comprises 0.1 mg, 0.3 mg, 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 9 mg, 10 mg, 12 mg, 18 mg, or 20 mg of the SARM compound of Formula I disclosed herein. In certain embodiments, the SARM compound is the compound of Formula IX.

[0044] In some embodiments, the Cmax obtained in vivo is reduced by from about 5% to about 75% for any given dose of said SARM compound compared to an immediate release dosage form of the same cumulative dose of said SARM compound. A lowered or reduced Cmax may facilitate maintaining effective concentrations of the SARM compound without exceeding a concentration that would lead to any adverse or untoward effects. Further, the delayed release formulations of the invention allow timing and location of SARM absorption to be adjusted to optimize coadministration with other APIs. In some embodiments, the other API may include weight loss drugs. In some embodiments, another API may include drugs for the treatment of breast cancer. In certain embodiments, the SARM compound is the compound of Formula IX.

[0045] In some embodiments, the Cmaxobtained in vivo is reduced by from about 5% to about 75%, or from about 5% to about 65%, or from about 5% to about 55%, or from about 5% to about 50%, or from about 5% to about 45%, or from 5% to about 40%, or from about 5% to about 35%, or from about 5% to about 30%, or from about 10% to about 50%, or from about 15% to about 60%, or from about 20% to about 50%, or from about 20% to about 40%, or from about 30% to about 55%, or from about 30% to about 40% for any given dose of said SARM compound compared to an immediate release dosage form of the same cumulative dose of said SARM compound. In certain embodiments, the SARM compound is the compound of Formula IX. In some embodiments, the AUC is not significantly changed compared to an immediate release dosage form. In some embodiments, the AUC is decreased compared to an immediate release dosage form. In some embodiments, the AUCinf is not significantly changed compared to an immediate release dosage form. In some embodiments, the AUCinf is decreased compared to an immediate release dosage form.

[0046] In some embodiments, the Cmax obtained in vivo is reduced by about 5%, about 10%, about 15%, about 20%, or about 25%, or about 30%, or about 35%, or about 40%, or about 45%, orP-657030-PCabout 50%, or about 55%, or about 60%, or about 65%, or about 70%, or about 75% for any given dose of said SARM compound compared to an immediate release dosage form of the same cumulative dose of said SARM compound. In certain embodiments, the SARM compound is the compound of Formula IX. In some embodiments, the AUC is not significantly changed compared to an immediate release dosage form. In some embodiments, the AUC is decreased compared to an immediate release dosage form. In some embodiments, the AUCinf is not significantly changed compared to an immediate release dosage form. In some embodiments, the AUCinf is decreased compared to an immediate release dosage form.

[0047] In some embodiments, the Cmax is reduced by about 15% to about 75% and the AUC is not significantly changed compared to an immediate release dosage form of the same cumulative dose. In some embodiments, the AUC is decreased compared to an immediate release dosage form of the same cumulative dose. In some embodiments, the Cmax is reduced by about 15% to about 75% and the AUCinf is not significantly changed compared to an immediate release dosage form of the same cumulative dose. In some embodiments, the AUCinf is decreased compared to an immediate release dosage form of the same cumulative dose. As a result, the oral delivery system of the invention provides a desired therapeutic effect while avoiding possible incidence of adverse or untoward effects that may exhibit in an immediate release formulation. In some cases, the delayed release formulations allow timing and location of SARM absorption to be adjusted to optimize coadministration with another API. In some embodiments, the other API may include weight loss drugs. In some embodiments, the other API may include drugs for the treatment of breast cancer. In some cases, the adjusted timing and location of SARM absorption are optimized for treatment of certain diseases or conditions. In some embodiments, the diseases and conditions may include treatment of obesity. In some embodiments, the diseases and conditions may include treatment of breast cancer. In certain embodiments, the SARM compound is the compound of Formula IX.

[0048] In some embodiments, the Tmax obtained in vivo is increased by about 10% to about 300% for any given dose of said SARM compound compared to an immediate release dosage form of the same dose of said SARM compound. In certain embodiments, the SARM compound is the compound of Formula IX.P-657030-PC

[0049] In some embodiments, the Tmaxobtained in vivo is increased from about 10% to about 300%, from about 20% to about 300%, from about 30% to about 300%, from about 40% to about 300%, from about 50% to about 300%, from about 60% to about 300%, from about 70% to about 300%, from about 80% to about 300%, from about 90% to about 300%, from about 100% to about 300%, from about 110% to about 300%, from about 120% to about 300%, from about 130% to about 300%, from about 140% to about 300%, from about 150% to about 300%, from about 160% to about 300%, from about 170% to about 300%, from about 180% to about 300%, from about 190% to about 300%, or from about 200% to about 300% for any given dose of said SARM compound compared to an immediate release dosage form of the same cumulative dose of said SARM compound. In certain embodiments, the SARM compound is the compound of Formula IX.

[0050] In some embodiments, the Tmax obtained in vivo is increased by from about 20% to about 300%, or from about 30% to about 275%, or from about 30% to about 250%, or from about 30% to about 225%, or from about 30% to about 200%, or from about 30% to about 175%, or from about 30% to about 150%, or from about 40% to about 150%, or from about 50% to about 150%, or from about 60% to about 150%, or from about 70% to about 150%, or from about 80% to about 150%, or from about 90% to about 150%, or from about 100% to about 150% for any given dose of said SARM compound compared to an immediate release dosage form of the same cumulative dose of said SARM compound. In certain embodiments, the SARM compound is the compound of Formula IX.

[0051] In some embodiments, the AUC obtained in vivo for any given dose of said SARM compound is from about 80% to about 125% of the AUC for an immediate release dosage form of the same cumulative dose of said SARM compound. In some embodiments, the AUCinf obtained in vivo for any given dose of said SARM compound is from about 80% to about 125% of the AUCinf for an immediate release dosage form of the same cumulative dose of said SARM compound. In certain embodiments, the SARM compound is the compound of Formula IX.

[0052] In some embodiments, the AUC or AUCinf obtained in vivo for any given dose of said SARM compound is from about 70% to about 130%, from about 80% to about 130%, from about 80% to about 110%; or from about 85% to about 105%; or from about 90% to about 120% of theP-657030-PCAUC or AUCinf for an immediate release dosage form of the same cumulative dose of said SARM compound. In certain embodiments, the SARM compound is the compound of Formula IX.

[0053] In some embodiments, the AUC or AUCinf obtained in vivo for any given dose of said SARM compound is from about 60%, 70%, 80%, 90%, 95%, 100%, 105%, 110%, 115%, 120%, 125%, or 130% of the AUC or AUCinf for an immediate release dosage form of the same cumulative dose of said SARM compound. In certain embodiments, the SARM compound is the compound of Formula IX.

[0054] In some embodiments, the Tmaxis increased by about 20% to about 300% and the AUC or AUCinf is not significantly changed compared to an immediate release dosage form. The delivery system of the invention continues to allow fast therapeutic action after a first release and further retains blood drug concentration for long periods after a second release.

[0055] As used herein, the term “not significantly changed” or “no significant change” refers to the concentration or the AUC (area under the concentration-time curve) of the formulation and shows no more than 10% variation of the AUC or AUCinf obtained in vivo for any given dose of said SARM compound with a range that is within 60-140%, or preferably 80-120%, of the AUC or AUCinf for an immediate release dosage form of the same cumulative dose of said SARM compound. In certain embodiments, the SARM compound is the compound of Formula IX.

[0056] In some embodiments, the concentration-time profile in vivo demonstrates two discreet absorption phases.

[0057] In some embodiments, the adverse effect profile with said system is improved compared to an immediate release dosage form delivering the same cumulative dose. In other embodiments, any adverse or untoward effects are better managed or reduced. In some embodiments, the adverse effect profile of a co-administered API is improved compared to an immediate release dosage form delivering the same cumulative dose. In some cases, the co-administered API is a weight loss drug or a breast cancer treatment.

[0058] The drug delivery system of the invention maintains beneficial aspects of the SARM compound disclosed herein of an immediate release formulation while substantially lowering theP-657030-PCmaximum plasma concentration (Cmax) for any efficacious dose, increasing the maximum tolerated dose, decreasing incidence or magnitude of adverse or untoward effects, or improving bioavailability or pharmacokinetic profile of the SARM compound. In some cases, the drug delivery system of the invention improves the beneficial aspects of the SARM compound disclosed herein when given for a particular disease or condition and / or when co-administered with other API’s; e.g., multiple APIs can be released together (from the same compartments) or can be separated in time by any desired time interval by incorporation into separate compartments and tuning A, B, C, D, D’, E, E’, and F as needed.

[0059] The selective androgen receptor modulator (SARM) compound as disclosed herein, or an optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an N-oxide, or a crystal of the SARM compound, can be prepared by methods as known in the art, e.g., U. S. Patent No. 9,604,916.

[0060] As used herein, the oral delivery system of the present invention may further include suitable diluents, preservatives, solubilizers, emulsifiers, adjuvants, additives, and / or carriers. In some embodiments, the formulations may be created by a 3-dimensional screen printing process (“3DP”). The 3DP process not only offers all the advantages of additive manufacturing, but is set to overcome the limitations of the “conventional” 3DP technologies. In particular, 3DP is best suited for mass customization of a drug delivery system relying on a conventional regulatory strategy. In 3DP, a screen mesh is used to transfer a semi-solid, API containing paste onto a substrate, except in areas made impermeable to the paste by a blocking stencil. The deposited layer is then dried through different drying methods. The next layer is printed precisely on top of the previous one after lifting the screen by the dried layer thickness. Regarding throughput, the number of units printed simultaneously is largely defined by the ratio of screen size to unit size. The cyclic process of 3DP is based on the classic flatbed screen printing process, which finds wide applications in industry for textile prints, large-format posters, traffic routing systems and signs, electronic circuit boards, membrane switches, electronic display boards and solar cell electrodes.3DP has been used in the development of ceramic and metal parts for small series industrial applications.

[0061] Studies demonstrated the power of the 3DP technology for generating fine structures andP-657030-PCparts with high resolution and precision even when using two different materials across different layers or within one and the same layer. Drug delivery systems of different geometries and sizes were printed based on pastes designed to yield various forms of API release. Given the mild conditions of the 3DP technology, a wide range of excipients and APIs can be processed. Results of standard analytics of the printed products established the feasibility of the approach thus providing proof-of-concept.

[0062] In preparing the formulation of the invention in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for solid oral formulation such as powders, capsules, and tablets including 3DP tablets of the invention (also referred to as the drug delivery system of the invention), suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like. Due to their ease in administration, tablets including the 3DP tablets of the invention, and capsules represent the most advantageous oral dosage unit form. If desired, 3DP tablets of the invention may be sugar coated or enteric coated by standard techniques.

[0063] In another aspect, the present invention provides a method (i) for preventing, reducing, or treating adverse effects caused by a weight loss drug or (ii) for maintenance or improvement of body composition in a subject who is in need of treatment with the weight loss drug, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, wherein the SARM is formulated by the drug delivery system of the invention as described herein. In some embodiments, the SARM compound is represented by a structure of Formula I, or an optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an N-oxide, or a crystal thereof, as disclosed herein. In one embodiment, the SARM compound is represented by a structure of Formula II as disclosed herein. In other embodiments, the SARM compound is represented by one of the structures of Formulas VIII, IX, X, XI, XII, XIII, and XIV as disclosed herein. In other embodiments, the SARM compound is represented by the structure of Formula IX as disclosed herein.

[0064] In some embodiments of the method of the invention, the subject has sarcopenic obesity, and / or the subject is 60 years old or older.P-657030-PC

[0065] In some embodiments, the weight loss drug is an incretin agonist or antagonist containing drug, wherein the incretin agonist or antagonist is a glucagon-like peptide-1 (GLP-1) receptor agonist, a glucose-dependent insulinotropic polypeptide (GIP) antagonist, or a GIP agonist, and / or a glucagon agonist, and / or an amylin agonist, and / or an oxyntomodulin agonist or any combination thereof. In certain embodiments, the incretin agonist or antagonist containing drug further contains an amylin mimetic.

[0066] In some embodiments, the incretin agonist or antagonist containing drug is any one of exenatide, exenatide LAR, liraglutide, taspoglutide, semaglutide, albiglutide, lixisenatide, tirzepatide, retatrutide, orforglipron, maritide, VK2735, or dulaglutide, or wherein the incretin agonist or antagonist containing drug is semaglutide.

[0067] In some embodiments, the adverse effects comprise one or more of loss in (i) lean body mass, fat-free mass, or muscle mass, (ii) muscle strength, (iii) physical function, (iv) bone strength, or (v) bone mass or density.

[0068] In some embodiments, the method of the invention prevents, reduces, or treats rebound of one or more of weight gain, fat mass gain, lean mass loss, and muscle strength or physical function loss when said weight loss drug is discontinued.

[0069] In some embodiments, the loss in lean body mass is from about 3% to 60% of the total body weight in the subject.

[0070] In some embodiments, the method of the invention results in one or more of (i) reducing the loss of lean body mass or gaining lean body mass (muscle mass) in the subject, (ii) preventing or reversing bone loss or gaining bone in the subject, (iii) overcoming or improving insulin resistance in the subject, and (iv) improving HbAlc in the subject.

[0071] In other embodiments, the method of the invention results in one or more of reducing abdominal, subcutaneous, or intramuscular fat accumulation, improving body composition, lowering body fat content, lowering fat mass, improving blood lipid profile, increasing or preserving muscle mass or muscle strength or muscle physical function, increasing or preserving bone mass or bone mineral density (BMD) or bone strength or bone function, and lowering HbAlcP-657030-PCin the subject.

[0072] In some embodiments, the method of the invention results in preservation or restoration of lean body mass (LBM) or muscle in the subject.

[0073] In some embodiments, the method of the invention prevents, reduces, or treats muscle weakness, poor balance, decreased gait speed, mobility disability, loss of independence, increased risk of falls, bone fractures, loss of physical function, physical disability, poor quality of life, high hospitalization rates, and / or increased mortality in the subject. In some embodiments, the bone fractures are fractures of the hip or pelvis in the subject.

[0074] In some embodiments, the SARM compound is administered to the subject concurrently with, or prior to, or after the treatment with the weight loss drug.

[0075] In some embodiments, the method of the invention prevents, reduces, or treats lean mass loss in a subject who is under treatment with the weight loss drug.

[0076] In some embodiments, the method of the invention decreases fat mass while preserving or increasing lean mass in the subject.

[0077] In some embodiments, the method of the invention improves physical function.

[0078] In some embodiments, the method of the invention further prevents, reduces, and / or treats muscle weakness, poor balance, decreased gait speed, mobility disability, loss of independence, increased risk of falls, bone fractures, loss of physical function, physical disability, poor quality of life, high hospitalization rates, and / or increased mortality in the subject. In some embodiments, the bone fractures are fractures of the hip or pelvis in the subject. In some embodiments, the subject has sarcopenic obesity, and / or the subject is 60 years old or older.

[0079] In some embodiments, the weight loss drug is an incretin agonist or antagonist containing drug selected from any one of exenatide, exenatide LAR, liraglutide, taspoglutide, semaglutide, albiglutide, lixisenatide, tirzepatide, retatrutide, orforglipron or dulaglutide. In certain embodiments, the incretin agonist or antagonist containing drug is semaglutide.P-657030-PC

[0080] In some embodiments, the method of the invention maintains or improves body composition in a subject who is under treatment with a weight loss drug.

[0081] In another aspect, the present invention provides a method for maintaining or improving body composition, and further maintaining or improving physical function or muscle strength, in a subject who is under treatment with the weight loss drug, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, wherein the SARM is formulated by the drug delivery system of the invention as described herein.

[0082] In some embodiments, the SARM compound is represented by a structure of Formula I, or an optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an N-oxide, or a crystal thereof, as disclosed herein. In one embodiment, the SARM compound is represented by a structure of Formula II as disclosed herein. In other embodiments, the SARM compound is represented by one of the structures of Formulas VIII, IX, X, XI, XII, XIII, and XIV as disclosed herein. In other embodiments, the SARM compound is represented by the structure of Formula IX as disclosed herein.

[0083] In some embodiments, the improved body composition is represented by further decreasing fat mass while preserving or increasing lean mass in a subject who is under treatment with said coadministered weight loss drug and said SARM compound, relative to a subject who is under treatment with the weight loss drug alone. In some embodiments, the physical function or muscle strength is maintained or improved.

[0084] In some embodiments, the subject has sarcopenic obesity, and / or the subject is 60 years old or older.

[0085] In some embodiments, the weight loss drug is an incretin agonist or antagonist containing drug, wherein the incretin agonist or antagonist is a glucagon-like peptide-1 (GLP-1) receptor agonist, a glucose-dependent insulinotropic polypeptide (GIP) antagonist, or a GIP agonist, and / or a glucagon agonist, and / or an amylin agonist, and / or an oxyntomodulin agonist or any combination thereof. In some embodiments, the incretin agonist or antagonist containing drug further contains an amylin mimetic.P-657030-PC

[0086] In some embodiments, the incretin agonist or antagonist containing drug is any one of exenatide, exenatide LAR, liraglutide, taspoglutide, semaglutide, albiglutide, lixisenatide, tirzepatide, retatrutide, orforglipron, maritide, VK2735, or dulaglutide, or wherein the incretin agonist or antagonist containing drug is semaglutide.

[0087] In certain embodiments, the SARM compound is represented by a structure of Formula IX.

[0088] In some embodiments, the incretin agonist or antagonist containing drug is semaglutide and the SARM is Formula IX.

[0089] In some embodiments, the method of the invention treats a subject suffering from breast cancer. In some embodiments, the breast cancer is at least one of said breast cancer is an AR-positive breast cancer, ER-positive breast cancer, triple negative breast cancer, HER2 -positive breast cancer, advanced breast cancer, refractory breast cancer, metastatic breast cancer, or breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI)(letrozole, anastrozole, exemestane), fulvestrant, cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Vorzenio), trilaciclib, lerociclib), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3 -kinase 5 subunit alpha (PI3K a)), mTOR inhibitor (everolimus), poly ADP ribose polymerase (PARP) inhibitor (olaparib (Lynparza) or talazoparib (Talzenna)), human epidermal growth factor receptor 2 (HER2) kinase inhibitor (lapatinib, neratinib (Nerlynx), dacomitinib (Vizimpro), or tucatinib (Tukysa)), HER2 antibody (trastuzumab (Herceptin), pertuzumab (Perjeta), margetuximab-cmkb (Margenza)), HER2 antibody drug conjugate (HER2 ADC) (am-trastuzumabderuxtecan-nxki (Enhertu), ado-trastuzumab emtansine (Kadcyla), or pertuzumab / trastuzumab / hyaluronidase-zzxf (Phesgo)), atezolizumab (Tecentriq) (PD-L1 blocking antibody), pembrolizumab (Keytruda) (PD-L1 blocking antibody), sacituzumab govitecan (Trodelvy) (antibody drug conjugate for TNBC), and / or bevacizumab (Avastin) treatments.

[0090] In some embodiments of the method of the invention, the SARM compound is administered at a cumulative dose of from 0.1 mg to 50 mg per day, or wherein the SARM compound is administered at a cumulative dose of 0.1 mg per day, 0.3 mg per day, 1 mg per day,P-657030-PC3 mg per day, 6 mg per day, 9 mg per day, or 18 mg per day.

[0091] As used herein, the terms “comprise”, "comprises", "comprising", "includes", "including", “having” and their conjugates mean "including but not limited to". The term “consisting of’ means “including and limited to”. The term "consisting essentially of means that the composition, method or structure may include additional ingredients, steps and / or parts, but only if the additional ingredients, steps and / or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.

[0092] As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a GLP-1 receptor agonist" or "at least one GLP-1 RAs" may include a plurality of GLP-1 RAs, including mixtures thereof.

[0093] Throughout this application, various embodiments of the present invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range. The phrases “between” a first indicated number and a second indicated number and “from” a first indicated number “to” a second indicated number are meant to include the first and second indicated numbers and all the fractional and integral numerals there between.

[0094] Unless otherwise defined, all technical and / or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and / or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are notP-657030-PCintended to be necessarily limiting. Each literature reference or other citation referred to herein is incorporated herein by reference in its entirety.

[0095] In the description presented herein, each of the steps of the invention and variations thereof are described. This description is not intended to be limiting and changes in the components, sequence of steps, and other variations would be understood to be within the scope of the present invention.

[0096] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.

[0097] In one embodiment, the term "administering" refers to bringing a subject in contact with a compound of the present disclosure. Administration can be accomplished in vitro, e.g. in a test tube, or in vivo, e.g., in cells or tissues of living organisms, for example humans. In some embodiments, the methods disclosed herein encompass administering the compounds of the present disclosure to a subject. In some embodiments, the present disclosure provides for the use of a SARM compound or its prodrug, analog, isomer, metabolite, derivative, pharmaceutically acceptable salt, pharmaceutical product, polymorph, crystal, impurity, / V-oxide, hydrate or any combination thereof, represented by one of the structures disclosed herein.

[0098] As used herein, in some embodiments, the term “3 mg Capsule” refers to an immediate release capsule formulation containing 3 mg Formula IX. As used herein, the delayed release tablets of the invention that contain the same cumulative amount of drug in their various compartments are compared to an immediate release formulation with the same cumulative dose. For example, Tab 358 and Tab 360 contain 1mg in Compartment 1 and 2 mg in Compartment 3 for a cumulative dose of 3mg of Formula IX, which is compared to the 3 mg Capsule containing 3 mg of Formula IX.P-657030-PC

[0099] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.EXAMPLE 1FORMULATIONS OF INVENTION

[0100] Table 1 and Figure 1 provide descriptions of Formulations Tab 358, Tab 359, Tab 360, Tab 365, and Tab 366.

[0101] Table 1: Formulations Tab 358, Tab 359, Tab 360, Tab 365, and Tab 366

[0102] As shown in Table 1, five different formulations were created by three-dimensional screening printing (3DP). Each formulation contained three compartments composed of the paste P242 (Compartment 1: an immediate (stomach) release compartment whose height is A), P287 (Compartment 2: an intestinal soluble buffer shell to protect Compartment 3 from gastric release whose height is B), and P276 (Compartment 3: an immediate or delayed release core compartment that dissolves in the intestine whose height is C). The composition of each paste is defined below in Tables 2-4. The heights (A, C, and D) correspond to the compartments identified in the following scheme:P-657030-PC

[0103] Table 2 provides a formulation for Compartment 1, an immediate release (IR) layer composed of the paste P242. Compartment 1 dissolves in the stomach to provide the first release of Formula IX (labeled as Enobosarm). The amount of Formula IX in Compartment 1, in these examples of the invention, depends on Height A (Scheme above). Tablets with A=0.5 mm deliver 1 mg of Formula IX from Compartment 1 (Tab 358, Tab 359, Tab 360) and tablets with A=1 mm deliver 2 mg of Formula IX from Compartment 1 (Tab 365 and Tab 366).

[0104] Table 2: Formulation of immediate release (IR) layer (P242) (Compartment 1)

[0105] Enobosarm is Formula IX and is the active pharmaceutical ingredient (API). The other representative ingredients listed in Table 2 have the Functions also listed in Table 2 which areP-657030-PCknown to the skilled artisan. For the purposes of the invention, suitable ingredients (excipients) in the same functional class as the listed ingredients (see “Function” column in the Tables 2, 3, and 4) and listed in FDA’s Inactive Ingredients Guide (Inactive Ingredients Database Download j FDA; htt s: / / w v.fda, goy approvai s-and-databasgs.dnactjve-ingredients-database-download, accessed May 13, 2026) are acceptable substitutes for the formulation.

[0106] Table 3 provides a formulation of Compartment 3 (Core compartment), another IR layer composed of the paste P287. Compartment 3 was protected from dissolving in the stomach by Compartment 2 (described below). Accordingly, Compartment 3 provided the second release of Formula IX. The amount of Formula IX in Compartment 3, in these examples of the invention, depends on Height C (scheme above). Tablets with C=0.28 mm deliver 2 mg of Formula IX from Compartment 3 (Tab 358, Tab 359, Tab 360) and tablets with C=0.14 mm deliver 1 mg of Formula IX from Compartment 3 (Tab 365 and Tab 366).

[0107] Table 3: Formulation of Core-P287 (Compartment 3)

[0108] In addition to the API, Compartment 3 contains a mucoadhesive binder that slows the transit of Compartment 3 through the intestine.

[0109] Table 4 provides a formulation of Compartment 2 (buffer layer) which is composed of paste P276. Compartment 2 was varied in geometry to increase or decrease the time interval between the 1stand 2ndrelease of the API, Formula IX, from Compartments 1 and 3. CompartmentP-657030-PC2 is insoluble in the stomach but soluble in the intestine. Accordingly, the time interval between the first and second release of Formula IX is increased as Height D and D’ are increased. Tab 358, Tab 359, Tab 360 had D=D’=0.1, 0.2, and 0.3 mm, respectively, whereas Tab 365 and Tab 366 had D=D’= 0.2 mm and 0.3 mm, respectively.

[0110] Table 4: Formulation of buffer layer - P276 (Compartment 2)

[0111] Compartment 2 lacks any API and instead contains several agents designed to slow transit through the gastrointestinal tract such as a gas formation agent (causes formulation to float) and a mucoadhesive binder.

[0112] The formulations described above are additively manufactured using a proprietary three-dimensional screening printing (3DP) process described herein to deposit the pastes into the separate compartments within the tablets with the relative geometries, as described above. These modified release formulations that cumulatively deliver 3 mg of Formula IX were tested in in vitro dissolution (Example 2) and in vivo oral pharmacokinetic experiments in pigs (Example 3) and humans (Example 4) to demonstrated their modified characteristics as compared to an various historical immediate release formulations of Formula IX. These included a hardshell powder-filled 3 mg capsules formulation referred to as 3 mg Capsule in Examples 2 and 3 or Hardshell Capsule in Example 4); and a liquid-filled soft gel capsule formulation referred to as SoftGel CapsulesP-657030-PC(Example 4).

[0113] The specific compartment dimensions and concentrations used in this example of the drug delivery system of the invention are not intended to limit the invention. It is understood by the skilled artisan that dimensions and concentrations can be increased or decreased in parallel to achieve the same alterations relative to IR formulations, such as immediate and delayed SARM release phases with adjustable time interval between release phases, and corresponding decreased Cmax, increased tmax and unaltered AUC values. Further, such adjustments to dimensions and concentrations can be made proportionally such that in vitro release and in vivo pharmacokinetic profiles are substantially unaltered. In some cases, tablets with width of <10 mm and heighth of <10 mm can be difficult to handle (poor handleability) and / or difficult to swallow. The invention includes drug delivery systems wherein the dimensions and concentrations are increased to address this issue.EXAMPLE 2RELEASE OF FORMULA IX FROM TABLETS IN RELEASE MEDIA(in vitro dissolution)

[0114] The study is to determine the active ingredient content of Formula IX released from Formula IX formulations in a release medium.

[0115] Definitions / Abbreviations (original language was German)P-657030-PC

[0116] Material

[0117] Formula IX Stock Solution and Formula IX Control Stock Solution [0.1 mg / mL]

[0118] Formula IX stock solution and Formula IX control stock solution were made in the same way. A 0.1 mg / mL Formula IX stock solution was prepared with Formula IX Standard by transferring 9.5 - 10.5 mg of Formula IX into a 100 mL volumetric flask, dissolving in approximately 80 mL of Diluent 1, and topping up to volume with Diluent 1 until Formula IX was completely dissolved.

[0119] The Formula IX control stock solution was produced in the same way in a second 100 mL volumetric flask.

[0120] The Formula IX stock solution and the Formula IX control stock solution were freshly prepared for the production of the standard solution and the standard control solution (KST), respectively.

[0121] Solution for Standard (Std) [0.01 mg / mL]: 10.0 mL of the Formula IX stock solution was transferred to a 100 mL volumetric flask and filled up to the volume mark with Diluent 2. The standard solution was made fresh before use.

[0122] Control Standard (KST) Solution [0.01 mg / mL]: 10.0 mL of the Formula IX Control Stock Solution was transferred to a 100 mL volumetric flask and filled up to the volume mark withP-657030-PCDiluent 2. The standard control solution was made fresh before use.

[0123] Blank Solution 1: Diluent 2 was used as blank solution 1.

[0124] Blank Solution 2: A mixture of release medium 1 (FSM 1) and release medium 2 (FSM 2) (3:1; v:v) was used as blank solution 2.

[0125] Release apparatus: Release apparatus for manual or automated release tests, e.g. the Agilent 708-DS Dissolution apparatus with integrated LCD touchscreen, paddles (USP Dissolution Apparatus II paddles)' and computer with Agilent Dissolution Workstation software (operational / control / protocol software), or any other apparatus with comparable or more technically advanced specifications.

[0126] HPLC-System: Liquid chromatograph with diode array detector (DAD), e.g. Thermo Scientific™ - Vanquish™ HPLC system (Thermo Fisher Scientific Inc.) with Vanquish™ diode array detector CG and computerized system with Chromeleon™ (evaluation software, Thermo Fisher Scientific Inc.), or any other system with comparable or more technically advanced specifications.

[0127] Dissolution: The number of tablets to be tested is specified according to the analysis order. Per tablet (active ingredient content of Formula IX is 3 mg), the release takes place in 500 g release medium 1 (FSM 1) per vessel (see ‘Method parameter dissolution’ section given below) for 2 hours (FSM 1 simulates stomach media). After the addition of 160 g of release medium 2 (FSM 2 simulates intestinal media), the dissolution is continued for 6 hours according to method LXM8 (given below). 1 mL sample per vessel is automatically taken per sampling time and filtered into an HPLC vial using a 0.45 µm PES filter and then analyzed by HPLC (see below).

[0128] Method parameter dissolution

[0129] Method parameters are for 1 vesselP-657030-PC

[0130] Injection sequence HPLC (1 vessel)

[0131] Testing of system suitability

[0132] Blank solution 1: The Blank Solution 1 has no peaks with the Retention time of Formula IX (TR = 2.9 min). Peaks with a signal-to-noise Ratio (S / N) of < 3 are not taken into account (signal-to-noise ratio rating according to USP <621>).

[0133] Blank solution 2: The Blank Solution 2 has no peaks with the Retention time of Formula IX (TR 2.9 min). Peaks with a signal-to-noise Ratio (S / N) of < 3 are not taken into account (signal-to-noise ratio rating according to USP <621>).P-657030-PC

[0134] Standard solution (hrs): The retention time (TR) of the active ingredient Formula IX is 2.9 min (standard deviation < 0.02 min).

[0135] Resolution: The resolution between the Formula IX-Peak (TR = 2.9 min) in the Standard solution and each adjacent peak should be > 1.5.

[0136] Precision of the system: The coefficient of variation (%RSD) of 5 analyses of the peak area of the Standard solution (Std) must not exceed 2.0%.

[0137] Peak symmetry: The Tailing factor of Formula IX-Peaks (TR = 2.9 min) in the Standard solution (hr) must be 0.8 - 1.8. (Determination according to USP <621>).

[0138] Sensitivity: That Signal-to-Noise Ratio (S / N) of the Formula IX-Peaks (TR = 2.9 min) in the Standard Solution (Std) should be > 10. (Evaluation of the signal-to-noise ratio according to USP <621>).

[0139] Control Standard: The Retention Time (TR) of the active ingredient Formula IX is 2.9 min (Standard deviation < 0.02 min). The control standard solution must not deviate by more than 2% from the peak area of Formula IX of the standard solution (mean value of the 5 injections of the standard solution). In the case of larger deviations, the measurements must be repeated before and after the failed control standard solution until a passed control standard (forward and backward in order) on the basis of a new calibration.AreaKST98% <MSTHrs <102%Cone. Std

[0140] Calculation

[0141] Calculation of the Concentration of the Standard Solution and Control Standard Solution

[0142] Calculation of the concentration of Formula IX in the Formula IX stock solution and Formula IX control stock solution:P-657030-PCmgi =mEnostamm mg] • P [%] ’ 0.01-Eno Stamm V [mL]

[0143] Calculation of the concentration of Formula IX in the standard solution and control standard solution:£ckncen$ratK>» of Formula EX in tfse Formula IXStaridsnd foiaSicrs (mg mt]Coecentratioe of Formul EX in t e Formula IX Control Standard Solution Img / ml]Weight of the Formula IX Standard for She formula IX Stock So fers [mg] Formula iX Standard Weight fsr Formula EX Control Stsris Solution [ gjParity sf the Fcrrwfe 1$ standard ac r iag ® Cs. [•%] nal lum» ©f F mt a IX stodc sslutiw sr Fcranab control stodkstiffen [ L]

[0144] Calculation of the concentration of the sample solution

[0145] The chromatograms are evaluated with the Chromeleon™ software installed.P-657030-PC

[0146] Calibrations are made for the active ingredient Formula IX using the standard solution. For this purpose, a linear regression according to the smallest squares of error is created by the axis origin (concentration standard solution against signal area). The Formula IX active ingredient contents of the individual samples are calculated by the determined signal area multiplied by the calibration function and the amount of solvent used in the sample processing.MM Average cd Formulaareas in the stamSartiscfetisrs (5-fold injection]M &rea s-f Formula LXin the trial’sa area of Formula IX from sample preparation at the respective samping timeConcentration of Formula IX m the Formula IX Standard SolutionVniun of sample s iutinn taken at the time of sampling [mlVolume of release esfem at tire respective semptog time {milI [zryj] Indicated amount of active i^redreiti: per tatitet [mg]

[0147] Results:

[0148] Figures 2 and 3 demonstrate the reproducibility of the release characteristics of the modified release formulations of Tab 360 and Tab 358, respectively, in dissolution testing in vitro. Each formulation (Tab 360 and Tab 358) was tested in triplicate. The results showed both formulations tested had two discrete releases of Formula IX. Figure 4 demonstrates that this is in contrast to the release profile of the 3 mg IR capsule which is superimposed with the release profiles of Tab 358 and Tab 360 in Figure 4. The three (3) dissolution profiles in Figure 4 demonstrated the difference in the immediate release, hardshell Formula IX 3 mg capsule (“3 mg Capsule”), and the two (2) formulations of the invention manufactured by 3DP process. The ability to control the timing of dissolution by varying the tablet design (varying compartment dimensions in this case) is demonstrated in Figures 2-4.

[0149] As expected, the immediate release capsule fully released its entire contents by 60 minutes,P-657030-PCwhile the two invention tablets showed a release of approximately 30 to 40% of their contents at 30 minutes while the release of the remainder is delayed until 90 to 150 minutes (Tab 358) and 150 to 240 minutes (Tab 360). This highly intentional control of the release of the drug permits the control of pharmacokinetic (PK) parameters when delivered in vivo such as reduced Cmax and increased Tmaxwhile maintaining or reducing AUC. These PK parameters can be manipulated based on alterations of the dimensions of A, B, C, D, D’, E, E’, and F (Scheme 1), as defined herein, that describe the Compartments 1, 2, and 3 incorporated into the modified release tablets. The delay in the release of Tabs 358 compared to 360 is due to an increase in the thickness of the Compartment 2 layer. E.g., the. Height D=D’ in Tab 358 of 0.1 mm was increased in Tab 360 to 0.3 mm, while all other dimensions were held constant (A = 0.5 mm; B = D+D’+C; C = 0.28 mm; and constant widths (E=E’ and F). This resulted in a longer delay until dissolution time of Compartment 3 and release of Formula IX in Tab 360. These dimensions could be varied in many different ways to achieve different delay times between releases. Further, different compartment shapes could be used to modulate dissolution times and concentration vs. time curve shapes. Cumulatively, these strategies can be used to optimize the pharmacokinetics of SARM release in vivo. In Example 3, to establish a proof-of-concept, the modified release Tabs 358 and 360 were compared in vivo in pigs to the immediate release 3 mg Capsule (hardshell capsule). Similarly, in Example 4, human modified release tablets of the invention were compared to the IR formulations of 3 mg hardshell capsules and 3 mg softgel capsules. Examples 3 and 4 demonstrated the ability to modulate in vivo pharmacokinetics based on tablet design using these scientific principles.EXAMPLE 3PHARMACOKINETIC STUDY IN PIGS OF DRUG CONCENTRATIONS IN THE BLOOD

[0150] This pharmacokinetic study is to investigate the absorption of the active substance (Formula IX) in the stomach and intestine after application using the drug delivery system of the invention. Drug concentrations were measured in the blood up to 34 hours after application.

[0151] After arrival of the study animals (pigs) to the laboratory, the pigs were kept separated forP-657030-PCat least two days for acclimatization. Fasted animals were moved without bedding two days before administration of the tablet to prevent solid bedding components being eaten during acclimatization, which would then have a relatively long retention time in the stomach, as this would be a hindrance to gastroscopic administration. For the period of fasting (24 hours, the animals had constant ad libitum access to drinking water), sufficient material (eg. cotton chews) was provided. After administration of the tablet and for the remainder of the experiment, the fasted animals were again kept on straw and given ad libitum food and water.

[0152] All animals received commercial age-appropriate feed ad libitum from the time of delivery until the end of the trial, with the exception of those animals for the period of fasting / fasting (max.24 hours before application of the tablets).

[0153] To determine the pharmacokinetic profile of the Formula IX dosage forms, blood samples (maximum blood volume per time point: 2 mb) were taken shortly before application of the tablets (time point 0 hours) and after application of the tablet (30, 60, 120, 240, 300, 330, 360, 480, 600 minutes and 24 and 34 hours) by puncturing the vena cava cranialis or vena jugularis with needles (21G to reduce pain during puncture) and monovettes. In order to reduce fixation stress and pain caused by the needle prick, blood sampling was performed exclusively by trained and experienced personnel. For the application of the tablet using a gastroscope (Olympus), the one-day fasted study animals were sedated (0.5 mg per kg body weight azaperone and 10 mg per kg body weight ketamine intravenously). A mouth wedge was placed in the animals' mouths to protect the gastroscope and prevent bite damage to the gastroscope. The tablet was always administered by a person familiar with the gastroscope. The tablet was fixed using gastroscopic accessories before application and the gastroscope with the fixed tablet was inserted into the stomach via the esophagus.

[0154] When blood samples were taken, the pigs were restrained by an assistant using restraint measures commonly used in routine veterinary practice (manual restraint). The amount of blood per animal did not exceed the recommended maximum for multiple blood sampling.

[0155] In the serum, the drug concentrations for Formula IX were determined by HPLC at each sampling time. All study animals were euthanized according to the standards of the profession at the earliest time after the end of the experiment (see section titled ‘Information on the methods ofP-657030-PCkilling’ below). The test animals were kept in the experiment for a period of 82 hours (from the time they were stabled without bedding until the last blood sample is taken 34 hours after application of the tablet).

[0156] Within the groups, the pharmacokinetic profiles of the individual animals were compared with each other over the course of time (descriptive statistics). A linear model would be used to compare the values at the same time points between the groups (pharmacokinetic profile (AUCo-360 and Cmax)). As there was no previous experience of the differences between the groups, both the descriptive statistics (course within the group) and the comparison between the groups were recorded in the evaluation.

[0157] Use of anesthesia, analgesia and other pain-relieving methods

[0158] The animals were anaesthetized as required during the experiment and at the end of the experiment according to routine procedures by intramuscular injection of ketamine hydrochloride (Narketan®, 25 mg / kg body weight) and azaperone (Stresnil®, 2 mg / kg body weight), or intravenous injection of both active substances (10 mg / kg body weight ketamine, 0.5 mg / kg azaperone). If necessary, ketamine was added to prevent premature awakening of the animals. At the end of the experiment, the animals are euthanized by intracardiac injection of T61® (1 ml / 10 kg body weight) under anaesthesia.

[0159] Application of endpoints

[0160] If any clinical abnormalities occurred during the experiment that required euthanasia (discontinuation criteria: loss of consciousness (except anesthesia for the administration of the tablet), central nervous system phenomena, shock, collapse), affected animals would be immediately sedated by Stresnil and azaperone injection (see above) and euthanized with an intracardiac administration of T61® (1 ml / 10 kg body weight) veterinary euthanisia solution. If clinical symptoms occurred during the experiment that require veterinary treatment, appropriate routine veterinary measures would be initiated, depending on the type of symptoms that occur. A decision on further use as a study animal must be made according to the clinical symptoms. In the event of an experiment being discontinued for the affected and treated animal, this would mean euthanasia under the above-mentioned procedure.

[0161] Information on the methods of killingP-657030-PC

[0162] All animals were euthanized under general anaesthesia by intracardiac administration of T61® (1 ml / 10 kg body weight) veterinary euthanasia solution.

[0163] Information on the use of avoidance, reduction and improvement of the use of animals

[0164] Replace avoidance: Testing of active ingredient absorption was only possible on living animals.

[0165] Reduce: Due to the multi-stage structure of the experiment, possible suffering was minimized, as only a maximum of 6 piglets were used and sampled in parallel. It could be assumed that fewer laboratory animals would be needed than planned. The trials could be terminated if the desired blood level profile was already achieved with the less complex novel oral dosage form.

[0166] Refine: By limiting fasting to a maximum of 24 hours before administration of the tablet, by using gastroscopic administration instead of surgery, and by taking blood samples by trained and experienced personnel, the suffering of the animals was reduced to a necessary level.

[0167] Description of the housing, husbandry and care conditions

[0168] All piglets were kept and reared on the farm of origin with their littermates. After weaning, the piglets were brought to the laboratory at around 6 weeks of age and kept there for at least 2 days for acclimatization. The laboratory was registered as a user and was licensed for animal study.

[0169] The animals are kept in groups of 6 animals on straw. Those animals that were fasted 24 hours before application were kept on rubber mats without bedding for a total of 48 hours to prevent bedding from being ingested. All minimum requirements for pig and laboratory animal husbandry were met. Adequate enrichment material was provided in the form of straw or, during fasting, in the form of cotton chews. The animals were given water and fed for free consumption, with the exception of those animals that were fasted. These animals were deprived of food for 24 hours. After euthanasia, the animal carcasses were made available for the removal of organs and other biological material for scientific purposes.

[0170] Reduction, prevention and alleviation of all suffering from birth to death

[0171] As described in the experimental procedure, all suffering was prevented, reduced and alleviated by reducing fasting to a necessary minimum, administering it in an animal-friendly way instead of surgery using a gastroscope and taking blood samples by trained, practiced andP-657030-PCexperienced personnel. After completion of the experiment (34 hours after application of the tablet), the animals were euthanized under general anesthesia.

[0172] Avoidance of unjustified duplication of animal testing (if applicable)

[0173] To our knowledge and according to our literature searches, no study has yet been conducted on these novel dosage forms of Formula IX and the absorption of the active ingredient after oral administration in pigs. Thus, a double, unjustified use of animal experiments is not applicable in this case. Furthermore, the aim of this study is to develop dosage forms that (i) reduce plasma spikes (i.e., lower Cmax and higher tmax) and (ii) achieve a favorable side effect profile. The data from this study are necessary for the further approval of a potential new dosage form of Formula IX for the treatment of patients with breast cancer and obesity.

[0174] Results: Figure 5 describes the concentration-time profiles which demonstrated the blood concentrations of Formula IX at various time points following oral administration. From the concentration-time plots, it was possible to demonstrate that the modified release Tab 358 and Tab 360 each had lowered Cmax, increased Tmax, and “unaltered-to- decreased” AUC values compared to the immediate release capsule, as predicted by in vitro experiments depicted in Figure 4.

[0175] Table 5: AUC Data

[0176] The comparable AUC confirmed for the IR Capsule, 3 mg, slightly exceeds that for the modified release formulations developed using the invention. The IR capsule tmax is about 120 min indicating that net Formula IX absorption phase was complete at this time point. In comparison, Tab 358 and Tab 360 had a prolonged net absorption phase of Formula IX with a tmax of at least 240 min. Also, the Cmax was reduced from about 155 ng / mL (3 mg IR Capsule) to about 130 ng / mL (Tab 358) and 75 mg / mL (Tab 360). Further, the combination of the initial release from Compartment 1 and the delayed release from Compartment 3 altered the terminal slope of the elimination phase indicating a longer duration of release observed for the modified formulationsP-657030-PCsince elimination half-lives (t1 / 2) would necessarily remain unchanged for each unique drug substance. Duration of action of the API would also be extended. These modified PK profiles provided confirmation of the ability of the invention to adjust PK profiles to optimize therapeutic and adverse effect profiles of SARM monotherapy or combination therapy. In this case, both modified release formulations reduced the Cmax and increased tmax while maintaining an acceptable AUC.EXAMPLE 4EVALUATION OF PLASMA CONCENTRATIONS VERSUS TIME PROFILES IN HUMANS OF DRUG DELIVERY SYSTEMS OF THE INVENTION

[0177] Two novel modified release oral formulations for Formula IX, a selective androgen receptor modulator for chronic weight loss management, were tested in human subjects and analyzed for pharmacokinetic (PK) endpoints in a clinical study. The data presented here were the initial five human subjects in the clinical trial.

[0178] The single dose, open label pilot study evaluated the plasma concentration versus time profile of two modified release formulations of Formula IX 3 mg. The two formulations are labeled as Formulation 1 (Form 1; same as Tab 358 in Examples 1-3) and Formulation 2 (Form 2; same as Tab 360 in Examples 1-3) in Figure 6 and Table 6, The new formulations demonstrated the intended distinct target product release profile, which included a reduction in maximum plasma concentration (Cmax), a delayed time to maximum plasma concentration (Tmax), a distinct secondary peak plasma concentration, and similar extent of absorption (AUC) compared to historical values for Formula IX immediate release capsules (Figure 6 and Table 6) The two novel formulations. Formulation 1 and Formulation 2, differed in the geometry of the tablets and were produced by a patented three-dimensional screen-printing technology owned by Laxxon Medical (Laxxon), as discussed further herein. Formulation 1 and Formulation 2 were compared to historical formulations of Formula IX, a powder-filled hard gel capsule (Hardshell Capsule in Table 6), and a liquid-filled soft gel capsule (Softgel Capsule in Table 6), which were both traditional formulations not employing the technology owned by Laxxon.P-657030-PC

[0179] Table 6: Pharmacokinetic Comparison of the Novel Formulations to Historical Formulations

[0180] Based on this PK (pharmacokinetic) data, Formulation 1 (same as Tab 358 in Examples 1-Phase4Ltmil 4ft-the-Obesty4h:0gFaffi-(see-bek^^

[0181] I he novel modified release oral formulations of Formula IX were developed using smart delivery systems, including Laxxon’s SPID®- Technology to create advanced, unique oral delivery release profiles, as well as an innovative additive manufacturing process. The intellectual property protecting this technology is extensive and includes, but is not limited to, U. S. Patent Nos. 11,986,558, 11,419,824, 12,115,130, 12,290,604, 12,290,605, 12,290,606, 12,290,607, and many others. SPID®-Technology unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities in drug development and commercialization.

[0182] The positive topline and safety results from the Phase 2b QUALITY clinical study were disclosed in U. S. Patent Application No. 19 / 248,412, filed June 24, 2025, which is a multicenter, double-blind, placebo-controlled, randomized, dose- finding clinical trial designed to evaluate the safety and efficacy of Formula IX 3 mg, Formula IX 6 mg, or placebo as a treatment to augment fat loss and to prevent muscle loss in 168 older patients (>60 years of age) receiving semaglutide (Wegovy®) for chronic weight management. These patients were not dosed with modified release oral formulations of this invention.

[0183] After completing the efficacy dose-finding portion of the Phase 2b QUALITY clinical trial,P-657030-PCparticipants continued into a Phase 2b maintenance extension study where all patients discontinued semaglutide treatment, but continued receiving placebo, Formula IX 3 mg, or Formula IX 6 mg as monotherapy in a double-blind fashion for 12 weeks. The positive results from the Phase 2b QUALITY and Maintenance Extension clinical study showed that Formula IX significantly reduced body weight regain, prevented fat regain, and preserved lean mass after semaglutide discontinuation. These patients were not dosed with modified release oral formulations of this invention.

[0184] In conclusion, the Phase 2b QUALITY and Maintenance Extension clinical trial confirms that preserving lean mass with Formula IX plus semaglutide led to greater fat loss during the active weight loss period, and after semaglutide was discontinued, Formula IX monotherapy significantly prevented the regain of both weight and fat mass during the maintenance period such that by end of study there was greater loss of fat mass while preserving lean mass for a higher quality weight reduction compared to the placebo group.

[0185] While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.

Claims

P-657030-PCCLAIMSWhat is claimed is:

1. An oral drug delivery system for a controlled administration of a selective androgen receptor modulator (SARM) compound of Formula I to a subject, the system comprising multiple distinct compartments comprising(i) Compartment 1: a first immediate release SARM-containing compartment that is soluble in the fluids of the stomach;(ii) Compartment 2: a base compartment without SARM that is contiguous with Compartment 1 and is insoluble in the stomach but soluble in the intestine,(iii) Compartment 3: a second (delayed) release SARM-containing compartment (the inner core or central core) that is completely enclosed by Compartment 2 such that its contents are protected until Compartment 2 dissolves in the intestine and causes the delayed release of Compartment 3 in the intestine;wherein said drug delivery system provides a dual release of said SARM compound in vivo characterized by a defined time interval between a first release of the SARM compound in stomach and a second release of the SARM compound in the intestine; wherein said SARM compound is represented by a structure of Formula I:whereinX is a bond, O, CH2, NH, S, Se, PR, NO, or NR;Gis O or S;T is OH, OR, -NHCOCH3, orNHCOR;R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, halogen, alkenyl, or OH;P-657030-PCRi is CH3, CH2F, CHF2, CF3, CH2CH3, or CF2CF3;R2is H, F, Cl, Br, I, CH3, CF3, OH, CN, NO2, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, N(R)2, or SR;Rs is H, F, Cl, Br, I, CN, NO2, COR, COOH, CONHR, CF3, or Sn(R)3, or Rs together with the benzene ring to which it is attached forms a fused ring system represented by the structure:Z is NO2, CN, COR, COOH, or CONHR;Y is CF3, F, Br, Cl, I, CN, or Sn(R)3;Q is CN, alkyl, halogen, N(R)2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R, or SR;or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B, or C:n is an integer of 1-4; andm is an integer of 1-3, oran optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an / V-oxide, or a crystal thereof.

2. The drug delivery system of claim 1, wherein said SARM is a compound of Formula II:P-657030-PCwhereinX is a bond, 0, CH2, NH, Se, PR, or NR;Gis O or S;T is OH, OR, -NHCOCH3, orNHCOR;Z is NO2, CN, COR, COOH, or CONHR;Y is I, CF3, Br, Cl, or Sn(R)3;Q is CN, alkyl, halogen, N(R)2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R, or SR;or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B, or C:R is a C1-C4 alkyl, aryl, phenyl, alkenyl, hydroxyl, a C1-C4 haloalkyl, halogen, or haloalkenyl; andRi is CH3, CF3, CH2CH3, or CF2CF3; oran optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an N-oxide, or a crystal thereof.

3. The drug delivery system of claim 1, wherein said SARM compound is represented by a structure of Formulas VIII, IX, X, XI, XII, XIII, or XIV:P-657030-PCP-657030-PCXIV, oran optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an V-oxide, or a crystal thereof.

4. The drug delivery system of claim 1, wherein said SARM compound of Formula I is represented by a structure of Formula IX:IX, oran optical isomer, a racemic mixture, a pharmaceutically acceptable salt, a pharmaceutical product, a hydrate, an / V-oxide, or a crystal thereof.

5. The drug delivery system of claim 1, wherein the relative compartment dimensions and / or compartment compositions are adjustable to allow the modification of said time interval between the first immediate release period and the second (delayed) release phase.

6. The drug delivery system of claim 1, wherein the relative dimensions and / or compartment compositions are adjustable to improve handleability and swallowability.

7. The drug delivery system of claim 6, wherein the dimensions and SARM concentrations are adjusted proportionally such that in vitro release and in vivo pharmacokinetic profiles are not altered.

8. The drug delivery system of claim 5, wherein the time interval between the first immediate release period and the second (delayed) release phase is from 0.5 hours to 12 hours.P-657030-PC9. The drug delivery system of claim 5, wherein the time interval between the first immediate release period and the second (delayed) release phase is from 1 hours to 6 hours.

10. The drug delivery system of claim 5, wherein the height or width of each compartment is varied in order to modify the timing of said second (delayed) release phase.

11. The drug delivery system of claim 5, wherein(a) said first immediate release compartment (a top compartment) has a height of from 0.1 mm to 5 mm (Height A),(b) said base compartment (in light shading) has a height of from 0.1 mm to 15 mm (Height B),(c) said second (delayed) release compartment (lower dark compartment) has a height of from 0.01 mm to 8 mm (Height C),wherein the height of the base compartment above the second (delayed) release compartment is from 0.01 mm to 3.5 mm (Height D),wherein the height of the base compartment below the second (delayed) release compartment is from 0.01 mm to 3.5 mm (Height D’),wherein the width of the base compartment on either side of the second (delayed) release compartment is from 0.01 mm to 10 mm (Widths E and E’),wherein the width of the second (delayed) release compartment is from 0.01 mm to 20 mm (width F);wherein the heights A, B, C, D, and D’ and widths E, E’, and F are as depicted below:P-657030-PC12. The drug delivery system of claim 1, wherein the first immediate release compartment (stomach soluble) comprises 0.1 mg to 20 mg of the SARM compound of Formula I.

13. The drug delivery system of claim 1, wherein the first immediate release compartment comprises 0.5 mg to 10 mg of the SARM compound of Formula I.

14. The drug delivery system of claim 1, wherein the second (delayed) release compartment (intestine soluble) comprises 0.1 mg to 20 mg of the SARM compound of Formula I.

15. The drug delivery system of claim 1, wherein the second (delayed) release compartment contains 0.5 mg to 10 mg of the SARM compound of Formula I.

16. The drug delivery system of claim 1, wherein the Cmax obtained in vivo is reduced by from about 5% to about 75% for any given dose of said SARM compound compared to an immediate release dosage form of the same cumulative dose of said SARM compound.

17. The drug delivery system of claim 1, wherein the Tmaxobtained in vivo is increased by about 20% to about 300% for any given dose of said SARM compound compared to an immediate release dosage form of the same cumulative dose of said SARM compound.

18. The drug delivery system of claim 1, wherein the AUC obtained in vivo for any given dose of said SARM compound is from about 80% to about 125%> of the AUC for an immediate release dosage form of the same cumulative dose of said SARM compound.

19. The drug delivery system of claim 1, wherein the Cmax is reduced by about 15% to 65% and the AUC is not significantly changed compared to an immediate release dosage form.

20. The drug delivery system of claim 1, wherein the Tmaxis increased by about 20% to 300% and the AUC is not significantly changed compared to an immediate release dosage form.

21. The drug delivery system of claim 1, wherein the concentration-time profile in vivo demonstrates two discreet absorption phases.

22. The drug delivery system of claim 1, wherein the adverse effect profile with said system is improved compared to an immediate release dosage form delivering the same cumulative dose.P-657030-PC23. A method for preventing, reducing, or treating adverse effects caused by a weight loss drug in a subject who is under treatment with the weight loss drug, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, wherein the SARM is formulated by the drug delivery system of claim 1.

24. The method according to claim 23, wherein said SARM compound is represented by a structure of Formula II:whereinX is a bond, O, CH2, NH, Se, PR, or NR;G is O or S;T is OH, OR, -NHCOCH3, or NHCOR;Z is NO2, CN, COR, COOH, or CONHR;Y is I, CF3, Br, Cl, or Sn(R)3;Q is CN, alkyl, halogen, N(R)2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R, or SR;or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B, or C:A B C;R is a C1-C4 alkyl, aryl, phenyl, alkenyl, hydroxyl, a C1-C4 haloalkyl, halogen, or haloalkenyl; andRi is CH3, CF3, CH2CH3, or CF2CF3.P-657030-PC25. The method according to claim 23, wherein said SARM compound is represented by a structure of Formulas VIII, IX, X, XI, XII, XIII, and XIV:P-657030-PCXII,XIV.

26. The method according to claim 23, wherein said SARM compound is represented by a structure of Formula IX,IX.

27. The method according to claim 23, wherein (i) the subject has sarcopenic obesity, and / or (ii) the subject is 60 years old or older.

28. The method according to claim 23, wherein the weight loss drug is an incretin agonist or antagonist containing drug, wherein the incretin agonist or antagonist is a glucagon-like peptide-1 (GLP-1) receptor agonist, a glucose-dependent insulinotropic polypeptide (GIP) antagonist, or aP-657030-PCGIP agonist, and / or a glucagon agonist, and / or an amylin agonist, and / or an oxyntomodulin agonist or any combination thereof.

29. The method according to claim 28, wherein the incretin agonist or antagonist containing drug further contains an amylin mimetic.

30. The method according to claim 28, wherein the incretin agonist or antagonist containing drug is any one of exenatide, exenatide LAR, liraglutide, taspoglutide, semaglutide, albiglutide, lixisenatide, tirzepatide, retatrutide, orforglipron, maritide, VK2735, or dulaglutide, or wherein the incretin agonist or antagonist containing drug is semaglutide.

31. The method according to claim 23, wherein the adverse effects comprise one or more of loss in (i) lean body mass, fat-free mass, or muscle mass, (ii) muscle strength, (iii) physical function, (iv) bone strength, or (v) bone mass or density.

32. The method according to claim 23, wherein the method prevents, reduces, or treats rebound of one or more of weight gain, fat mass gain, lean mass loss, and muscle strength or physical function loss when said weight loss drug is discontinued.

33. The method according to claim 31, wherein the loss in lean body mass is from about 3% to 60% of the total body weight in the subject.

34. The method according to claim 23, wherein the method results in one or more of (i) reducing the loss of lean body mass or gaining lean body mass (muscle mass) in the subject, (ii) preventing or reversing bone loss or gaining bone in the subject, (iii) overcoming or improving insulin resistance in the subject, and (iv) improving HbAlc in the subject.

35. The method according to claim 23, wherein the method results in one or more of reducing abdominal, subcutaneous, or intramuscular fat accumulation, improving body composition, lowering body fat content, lowering fat mass, improving blood lipid profile, increasing or preserving muscle mass or muscle strength or muscle physical function, increasing bone mass or bone mineral density (BMD) or bone strength or bone function, and lowering HbAl c in the subject.P-657030-PC36. The method according to claim 23, wherein the method results in preservation or restoration of lean body mass (LBM) or muscle in the subject.

37. The method according to claim 23, wherein the method prevents, reduces, or treats muscle weakness, poor balance, decreased gait speed, mobility disability, loss of independence, increased risk of falls, bone fractures, loss of physical function, physical disability, poor quality of life, high hospitalization rates, and / or increased mortality in the subject.

38. The method according to claim 37, wherein the bone fractures are fractures of the hip or pelvis in the subject.

39. The method according to claim 23, wherein said SARM compound is administered to the subject concurrently with, or prior to, or after the treatment with the weight loss drug.

40. The method according to claim 23, wherein said method prevents, reduces, or treats lean mass loss in a subject who is under treatment with the weight loss drug.

41. The method according to claim 40, wherein the method decreases fat mass while preserving or increasing lean mass in the subject.

42. The method according to claim 40 or 41, wherein the method improves physical function.

43. The method according to claim 40, further preventing, reducing, and / or treating muscle weakness, poor balance, decreased gait speed, mobility disability, loss of independence, increased risk of falls, bone fractures, loss of physical function, physical disability, poor quality of life, high hospitalization rates, and / or increased mortality in the subject.

44. The method according to claim 43, wherein the bone fractures are fractures of the hip or pelvis in the subject.

45. The method according to claim 40, wherein (i) the subject has sarcopenic obesity, and / or (ii) the subject is 60 years old or older.P-657030-PC46. The method according to claim 40, wherein the weight loss drug is an incretin agonist or antagonist containing drug selected from any one of exenatide, exenatide LAR, liraglutide, taspoglutide, semaglutide, albiglutide, lixisenatide, tirzepatide, retatrutide, orforglipron or dulaglutide.

47. The method according to claim 46, wherein the incretin agonist or antagonist containing drug is semaglutide.

48. The method according to claim 23, wherein said method maintains or improves body composition in a subject who is under treatment with a weight loss drug.

49. The method according to claim 48, wherein said SARM compound is represented by a structure of Formula II:whereinX is a bond, O, CH2, NH, Se, PR, or NR;G is O or S;T is OH, OR, -NHCOCH3, or NHCOR;Z is NO2, CN, COR, COOH, or CONHR;Y is I, CF3, Br, Cl, or Sn(R)3;Q is CN, alkyl, halogen, N(R)2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R, or SR;or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B, or C:P-657030-PCA B C;R is a C1-C4 alkyl, aryl, phenyl, alkenyl, hydroxyl, a C1-C4 haloalkyl, halogen, or haloalkenyl; andRi is CH3, CF3, CH2CH3, or CF2CF3.

50. The method according to claim 48, wherein said SARM compound is represented by a structure of Formulas VIII, IX, X, XI, XII, XIII, and XIV:P-657030-PCXIV.

51. The method according to claim 48, wherein said SARM compound is represented by a structure of Formula IX,P-657030-PCIX.

52. The method according to claim 48, wherein said improved body composition is represented by further decreasing fat mass while preserving or increasing lean mass in a subject who is under treatment with said co-administered weight loss drug and said SARM compound, relative to a subject who is under treatment with the weight loss drug alone.

53. The method according to claim 52, wherein the physical function or muscle strength is maintained or improved.

54. The method according to claim 48, wherein (1) the subject has sarcopenic obesity, and / or (2) the subject is 60 years old or older.

55. The method according to claim 48, wherein the weight loss drug is an incretin agonist or antagonist containing drug, wherein the incretin agonist or antagonist is a glucagon-like peptide-1 (GLP-1) receptor agonist, a glucose-dependent insulinotropic polypeptide (GIP) antagonist, or a GIP agonist, and / or a glucagon agonist, and / or an amylin agonist, and / or an oxyntomodulin agonist or any combination thereof.

56. The method according to claim 55, wherein the incretin agonist or antagonist containing drug further contains an amylin mimetic.

57. The method according to claim 55, wherein the incretin agonist or antagonist containing drug is any one of exenatide, exenatide LAR, liraglutide, taspoglutide, semaglutide, albiglutide, lixisenatide, tirzepatide, retatrutide, orforglipron, maritide, VK2735, or dulaglutide, or wherein the incretin agonist or antagonist containing drug is semaglutide.

58. The method according to claim 52 or 53, wherein said SARM compound is represented by a structure of Formula IX,P-657030-PCIX.

59. The method according to any one of claims 48, 52, or 53, where said incretin agonist or antagonist containing drug is semaglutide and said SARM is Formula IX.

60. The method of use of the SARM-containing drug delivery system of claim 1, wherein said method treats a subject suffering from breast cancer.

61. The method of claim 60, wherein said breast cancer is at least one of said breast cancer is an AR-positive breast cancer, ER-positive breast cancer, triple negative breast cancer, HER2-positive breast cancer, advanced breast cancer, refractory breast cancer, metastatic breast cancer, or breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (Al)(letrozole, anastrozole, exemestane), fulvestrant, cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Vorzenio), trilaciclib, lerociclib), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3 -kinase 5 subunit alpha (PI3K a)), mTOR inhibitor (everolimus), poly ADP ribose polymerase (PARP) inhibitor (olaparib (Lynparza) or talazoparib (Talzenna)), human epidermal growth factor receptor 2 (HER2) kinase inhibitor (lapatinib, neratinib (Nerlynx), dacomitinib (Vizimpro), or tucatinib (Tukysa)), HER2 antibody (trastuzumab (Herceptin), pertuzumab (Perjeta), margetuximab-cmkb (Margenza)), HER2 antibody drug conjugate (HER2 ADC) (am-trastuzumabderuxtecan-nxki (Enhertu), ado-trastuzumab emtansine (Kadcyla), or pertuzumab / trastuzumab / hyaluronidase-zzxf (Phesgo)), atezolizumab (Tecentriq) (PD-L1 blocking antibody), pembrolizumab (Keytruda) (PD-L1 blocking antibody), sacituzumab govitecan (Trodelvy) (antibody drug conjugate for TNBC), and / or bevacizumab (Avastin) treatments.

62. The method according to any one of claims 23 or 48, wherein the SARM compound is administered at a cumulative dose of from 0.1 mg to 50 mg per day, or wherein the SARM compound is administered at a cumulative dose of 0.1 mg per day, 0.3 mg per day, 1 mg per day, 3 mg per day, 6 mg per day, 9 mg per day, or 18 mg per day.